In a pilot study, the recombinant PANVAC poxviral vaccine (containing transgenes for CEA and MUC-1 and three T cell costimulatory molecules) was tested in 12 heavily pretreated metastatic BC patients. The gene discussed is MUC1; the disease is breast cancer.